Medroxyprogesterone Acetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326869

CAS#: 71-58-9

Description: Medroxyprogesterone Acetate, also known as MPA, is a steroidal progestin, a synthetic variant of the steroid hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is almost always being referred to is MPA and not MP It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system.

Price and Availability

Size Price Shipping out time Quantity
1g USD 250 2 Weeks
2g USD 450 2 Weeks
5g USD 650 2 Weeks
10g USD 950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

Medroxyprogesterone Acetate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326869
Name: Medroxyprogesterone Acetate
CAS#: 71-58-9
Chemical Formula: C24H34O4
Exact Mass: 386.2457
Molecular Weight: 386.532
Elemental Analysis: C, 74.58; H, 8.87; O, 16.56

Synonym: Medroxyprogesterone Acetate, MPA.

IUPAC/Chemical Name: (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate


InChi Code: InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

SMILES Code: CC([C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])C[C@H](C)C4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O

Technical Data

White to off-white crystalline powder.

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception. 2016 Sep;94(3):202-15. doi: 10.1016/j.contraception.2016.02.003. Epub 2016 Feb 10. Review. PubMed PMID: 26874275.

2: Brind J, Condly SJ, Mosher SW, Morse AR, Kimball J. Risk of HIV Infection in Depot-Medroxyprogesterone Acetate (DMPA) Users: A Systematic Review and Meta-analysis. Issues Law Med. 2015 Autumn;30(2):129-39. Review. PubMed PMID: 26710371.

3: Stanczyk FZ, Bhavnani BR. Reprint of "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?". J Steroid Biochem Mol Biol. 2015 Sep;153:151-9. doi: 10.1016/j.jsbmb.2015.08.013. Epub 2015 Aug 19. Review. PubMed PMID: 26291834.

4: Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review. PubMed PMID: 25118836.

5: Stanczyk FZ, Bhavnani BR. Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? J Steroid Biochem Mol Biol. 2014 Jul;142:30-8. doi: 10.1016/j.jsbmb.2013.11.011. Epub 2013 Nov 26. Review. PubMed PMID: 24291402.

6: Curry L, Taylor L, Pallas SW, Cherlin E, Pérez-Escamilla R, Bradley EH. Scaling up depot medroxyprogesterone acetate (DMPA): a systematic literature review illustrating the AIDED model. Reprod Health. 2013 Aug 2;10:39. doi: 10.1186/1742-4755-10-39. Review. PubMed PMID: 23915274; PubMed Central PMCID: PMC3737048.

7: Guirguis-Blake J. Copper intrauterine device vs. depot medroxyprogesterone acetate for contraception. Am Fam Physician. 2011 Jan 1;83(1):35-6. Review. PubMed PMID: 21888124.

8: Gerlach LS, Saldaña SN, Wang Y, Nick TG, Spigarelli MG. Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents. Clin Ther. 2011 Feb;33(2):182-7. doi: 10.1016/j.clinthera.2011.02.008. Epub 2011 Mar 12. Review. PubMed PMID: 21397330.

9: Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables--depot medroxyprogesterone acetate or norethisterone enantate? Contraception. 2009 Oct;80(4):391-408. doi: 10.1016/j.contraception.2009.03.023. Epub 2009 Jun 13. Review. PubMed PMID: 19751863.

10: Madeddu C, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009 Jun;10(8):1359-66. doi: 10.1517/14656560902960162. Review. PubMed PMID: 19445562.

11: Guilbert ER, Brown JP, Kaunitz AM, Wagner MS, Bérubé J, Charbonneau L, Francoeur D, Gilbert A, Gilbert F, Roy G, Senikas V, Jacob R, Morin R. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception. 2009 Mar;79(3):167-77. doi: 10.1016/j.contraception.2008.10.016. Epub 2009 Jan 15. Review. PubMed PMID: 19185668.

12: Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):387-95. doi: 10.1038/ncpcardio1234. Epub 2008 Jun 3. Review. PubMed PMID: 18521110.

13: Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet. 2008 Jul;278(1):1-12. doi: 10.1007/s00404-007-0497-z. Epub 2008 May 10. Review. PubMed PMID: 18470526.

14: Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008 Feb;77(2):67-76. doi: 10.1016/j.contraception.2007.10.005. Review. PubMed PMID: 18226668.

15: Simoncini T, Mannella P, Pluchino N, Genazzani AR. Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels. Gynecol Endocrinol. 2007 Oct;23 Suppl 1:9-16. Review. PubMed PMID: 17943534.

16: Shulman LP. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. J Womens Health (Larchmt). 2006 Jun;15(5):584-90. Review. PubMed PMID: 16796485.

17: Black A; Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa). J Obstet Gynaecol Can. 2006 Apr;28(4):305-13. English, French. PubMed PMID: 16776909.

18: Lo SS, Fan SY; Health Services Subcommittee of the Family Planning Association of Hong Kong. Bone loss associated with long-term use of depot medroxyprogesterone acetate. Hong Kong Med J. 2005 Dec;11(6):491-5. Review. PubMed PMID: 16340026.

19: Ortmann J, Traupe T, Vetter W, Barton M. [Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate]. Praxis (Bern 1994). 2004 May 19;93(21):904-14. Review. German. PubMed PMID: 15216975.

20: Busen NH. Bone mineral density in adolescent women using depot medroxyprogesterone acetate. J Am Acad Nurse Pract. 2004 Feb;16(2):57-62. Review. Erratum in: J Am Acad Nurse Pract. 2004 May;16(5):186. PubMed PMID: 15055422.